Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

Inclusion Criteria: * Male or female patients, 18-85 years of age and a weight of \> 45 kilograms. * Patients with intravascular catheters and a blood culture that is positive for gram-positive cocci in clusters. Patients will be subsequently excluded from the study analysis if they do not have a culture-positive infection with S. epidermidis or other coagulase negative staphylococci, expected to be susceptible to tigecycline. * Patients in whom the bacteremia can be cultured daily by the site investigator. * Patients who have failed other available antibiotic therapies may be enrolled with positive blood cultures and organism susceptibility to tigecycline. Exclusion Criteria: * Patients that cannot be cultured daily by the site investigator. * Intravascular catheter infections known to be caused by bacteria other than a coagulase negative staphylococci, for example, Staphylococcus aureus. * Any patient who has received more than 24 hrs of vancomycin. * Any patient who has received any antibiotic active against S. epidermidis other than vancomycin. * Patients who are moribund with an expected survival of less than 2 weeks. * Patients who are neutropenic (ANC \<500) at the time of bacteremia * Patients who have been designated as "Do Not Resuscitate", unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from tigecycline therapy. * Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents. * Pregnant women or nursing mothers. * Female patients of childbearing potential who do not agree to use a medically acceptable method of contraception throughout the duration of the study and for at least 1 month after the last dose of tigecycline. * Patients with suspected or proven endocarditis or osteomyelitis * Patients with suspected or proven mycobacterial infections